Filing Details
- Accession Number:
- 0000914190-21-000403
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-03 17:29:57
- Reporting Period:
- 2021-11-01
- Accepted Time:
- 2021-11-03 17:29:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 842023 | Bio-Techne Corp | TECH | Biological Products, (No Disgnostic Substances) (2836) | 411427402 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1603594 | James Hippel | 614 Mckinley Place N.e. Minneapolis MN 55413 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-11-01 | 8,822 | $125.05 | 19,577 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-11-01 | 3,566 | $525.61 | 16,011 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-01 | 2,880 | $526.50 | 13,131 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-01 | 1,433 | $527.50 | 11,698 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-01 | 943 | $528.55 | 10,755 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-11-02 | 200 | $125.05 | 10,955 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-11-02 | 200 | $525.10 | 10,755 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2021-11-01 | 8,822 | $0.00 | 8,822 | $125.05 |
| Common Stock | Stock Options (Right to Buy) | Disposition | 2021-11-02 | 200 | $0.00 | 200 | $125.05 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 47,589 | 2024-08-09 | No | 4 | M | Direct | |
| 47,389 | 2024-08-09 | No | 4 | M | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | $177.32 | 2025-08-08 | 18,066 | 18,066 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $177.32 | 2025-08-08 | 24,089 | 24,089 | Direct | |
| Common Stock | Restricted Stock Units | $0.00 | 3,938 | 3,938 | Direct | ||
| Common Stock | Stock Options (Right to Buy) | $190.41 | 2026-08-07 | 19,936 | 19,936 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $190.41 | 2026-08-07 | 26,581 | 26,581 | Direct | |
| Common Stock | Restricted Stock Units | $0.00 | 3,219 | 3,219 | Direct | ||
| Common Stock | Stock Options (Right to Buy) | $267.87 | 2027-08-05 | 14,360 | 14,360 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $267.87 | 2027-08-05 | 19,147 | 19,147 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $267.87 | 2027-08-05 | 8,325 | 8,325 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $267.87 | 2027-08-05 | 8,325 | 8,325 | Direct | |
| Common Stock | Restricted Stock Units | $0.00 | 1,945 | 1,945 | Direct | ||
| Common Stock | Stock Options (Right to Buy) | $481.82 | 2028-08-06 | 7,600 | 7,600 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $481.82 | 2028-08-06 | 10,134 | 10,134 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2025-08-08 | 18,066 | 18,066 | Direct |
| 2025-08-08 | 24,089 | 24,089 | Direct |
| 3,938 | 3,938 | Direct | |
| 2026-08-07 | 19,936 | 19,936 | Direct |
| 2026-08-07 | 26,581 | 26,581 | Direct |
| 3,219 | 3,219 | Direct | |
| 2027-08-05 | 14,360 | 14,360 | Direct |
| 2027-08-05 | 19,147 | 19,147 | Direct |
| 2027-08-05 | 8,325 | 8,325 | Direct |
| 2027-08-05 | 8,325 | 8,325 | Direct |
| 1,945 | 1,945 | Direct | |
| 2028-08-06 | 7,600 | 7,600 | Direct |
| 2028-08-06 | 10,134 | 10,134 | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.10 to $526.09, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.105 to $527.08, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.14 to $528.00, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.16 to $528.995, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
- Fully exercisable.
- Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022.
- Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
- Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024.
- Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
- Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
- Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Options to purchase 2,534 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 2,533 shares vest on each of 8/6/2024 and 8/6/2025.
Billionaire Hedge Funds
